Abstract
OBJECTIVE- Exenatide improves postprandial glycemic excursions in type 2 diabetes. Exenatide could benefit type 1 diabetes as well. We aimed to determine an effective and safe glucose-lowering adjuvant exenatide dose in adolescents with type 1 diabetes. RESEARCH DESIGN AND METHODS- Eight subjects completed a three-part double-blinded randomized controlled study of premeal exenatide. Two doses of exenatide (1.25 and 2.5 μg) were compared with insulin monotherapy. Prandial insulin dose was reduced by 20%. Gastric emptying and hormones were analyzed for 300 min postmeal. RESULTS- Treatment with both doses of exenatide versus insulin monotherapy significantly reduced glucose excursions over 300 min (P < 0.0001). Exenatide administration failed to suppress glucagon but delayed gastric emptying (P < 0.004). CONCLUSIONS- Adjunctive exenatide therapy reduces postprandial hyperglycemia in adolescents with type 1 diabetes. This reduction in glucose excursion occurs despite reduction in insulin dose. We suggest that exenatide has therapeutic potential as adjunctive therapy in type 1 diabetes.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1294-1296 |
| Number of pages | 3 |
| Journal | Diabetes Care |
| Volume | 33 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2010 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Advanced and Specialized Nursing
Cite this
The role of adjunctive exenatide therapy in pediatric type 1 diabetes. / Raman, Vandana S.; Mason, Kimberly J.; Rodriguez, Luisa M.; Hassan, Krishnavathana; Yu, Xiaoying; Bomgaars, Lisa; Heptulla, Rubina A.
In: Diabetes Care, Vol. 33, No. 6, 06.2010, p. 1294-1296.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The role of adjunctive exenatide therapy in pediatric type 1 diabetes
AU - Raman, Vandana S.
AU - Mason, Kimberly J.
AU - Rodriguez, Luisa M.
AU - Hassan, Krishnavathana
AU - Yu, Xiaoying
AU - Bomgaars, Lisa
AU - Heptulla, Rubina A.
PY - 2010/6
Y1 - 2010/6
N2 - OBJECTIVE- Exenatide improves postprandial glycemic excursions in type 2 diabetes. Exenatide could benefit type 1 diabetes as well. We aimed to determine an effective and safe glucose-lowering adjuvant exenatide dose in adolescents with type 1 diabetes. RESEARCH DESIGN AND METHODS- Eight subjects completed a three-part double-blinded randomized controlled study of premeal exenatide. Two doses of exenatide (1.25 and 2.5 μg) were compared with insulin monotherapy. Prandial insulin dose was reduced by 20%. Gastric emptying and hormones were analyzed for 300 min postmeal. RESULTS- Treatment with both doses of exenatide versus insulin monotherapy significantly reduced glucose excursions over 300 min (P < 0.0001). Exenatide administration failed to suppress glucagon but delayed gastric emptying (P < 0.004). CONCLUSIONS- Adjunctive exenatide therapy reduces postprandial hyperglycemia in adolescents with type 1 diabetes. This reduction in glucose excursion occurs despite reduction in insulin dose. We suggest that exenatide has therapeutic potential as adjunctive therapy in type 1 diabetes.
AB - OBJECTIVE- Exenatide improves postprandial glycemic excursions in type 2 diabetes. Exenatide could benefit type 1 diabetes as well. We aimed to determine an effective and safe glucose-lowering adjuvant exenatide dose in adolescents with type 1 diabetes. RESEARCH DESIGN AND METHODS- Eight subjects completed a three-part double-blinded randomized controlled study of premeal exenatide. Two doses of exenatide (1.25 and 2.5 μg) were compared with insulin monotherapy. Prandial insulin dose was reduced by 20%. Gastric emptying and hormones were analyzed for 300 min postmeal. RESULTS- Treatment with both doses of exenatide versus insulin monotherapy significantly reduced glucose excursions over 300 min (P < 0.0001). Exenatide administration failed to suppress glucagon but delayed gastric emptying (P < 0.004). CONCLUSIONS- Adjunctive exenatide therapy reduces postprandial hyperglycemia in adolescents with type 1 diabetes. This reduction in glucose excursion occurs despite reduction in insulin dose. We suggest that exenatide has therapeutic potential as adjunctive therapy in type 1 diabetes.
UR - http://www.scopus.com/inward/record.url?scp=77956074558&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956074558&partnerID=8YFLogxK
U2 - 10.2337/dc09-1959
DO - 10.2337/dc09-1959
M3 - Article
C2 - 20332358
AN - SCOPUS:77956074558
VL - 33
SP - 1294
EP - 1296
JO - Diabetes Care
JF - Diabetes Care
SN - 1935-5548
IS - 6
ER -